{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:55:16Z","timestamp":1785412516296,"version":"3.56.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"21","license":[{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5,23]]},"abstract":"<jats:p>Fasudil hydrochloride is used as a therapeutic agent for cerebral vasospasm after aneurysmal subarachnoid hemorrhage surgery; however, its limited efficacy necessitates additional treatment options. Although the therapeutic potential of cilostazol for improved outcomes after aneurysmal subarachnoid hemorrhage has been reported, no clinical studies have examined the effects of administering both cilostazol and fasudil hydrochloride on mortality and physical disability in patients. Therefore, we investigated the impact of combined fasudil hydrochloride and cilostazol administration among patients with subarachnoid hemorrhage (SAH) in Japan. A cross-sectional study was conducted using the diagnosis procedure combination database among patients with SAH who received fasudil hydrocholoride alone (n\u2005=\u20058728) or in combination with cilostazol (n\u2005=\u20058052) between April 2016 and March 2020. The primary endpoint was in-hospital mortality, and the secondary endpoint was the proportion of patients with a modified Rankin Scale (mRS) score\u2005\u22642 at discharge. Statistical analysis was performed using multivariate-adjusted logistic regression analysis with a significance level of 5%. The mean age was 63.8 years (standard deviation [SD]: 14.4) in the fasudil hydrochloride monotherapy group (F group) and 62.8 years (SD: 14.3) in the fasudil hydrochloride and cilostazol combination group (FC group). Female patients accounted for 69.5% in the F group and 70.1% in the FC group. The in-hospital mortality rate was 7.4% in the F group and 4.0% in the FC group. Patients in the FC group had a lower in-hospital mortality rate than did those in the F group (odds ratio 0.28, 95% confidence interval [CI] 0.23\u20130.34, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.001). The proportion of patients with an mRS score\u2005\u22642 at discharge was 49.4% in the F group and 55.7% in the FC group. Patients in the FC group had a higher mRS score\u2005\u22642 at discharge than those in the F group (odds ratio 1.43, 95% CI: 1.31\u20131.55, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.001). We investigated the impact of combined fasudil hydrochloride and cilostazol administration on the prognosis of Japanese patients with SAH. The results suggest that combination therapy with fasudil hydrochloride and cilostazol may have a synergistic effectiveness on improving SAH prognosis compared with fasudil hydrochloride monotherapy. In future, research is needed to understand the mechanisms underlying the combined use of cilostazol.<\/jats:p>","DOI":"10.1097\/md.0000000000042544","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T04:00:52Z","timestamp":1748318452000},"page":"e42544","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Prognosis of patients with aneurysmal subarachnoid hemorrhage treated with fasudil hydrochloride\u2013cilostazol combination therapy: A cross-sectional analysis of a nationwide inpatient database, 2016 to 2020"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-8344-4543","authenticated-orcid":false,"given":"Hiroshi","family":"Magara","sequence":"first","affiliation":[{"name":"Department of Drug Safety and Risk Management, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuaki","family":"Tani","sequence":"additional","affiliation":[{"name":"Department of Pharmacoepidemiology, Showa University Graduate School of Pharmacy, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinobu","family":"Imai","sequence":"additional","affiliation":[{"name":"Department of Pharmacoepidemiology, Showa University Graduate School of Pharmacy, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Drug Safety and Risk Management, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyohide","family":"Fushimi","sequence":"additional","affiliation":[{"name":"Department of Health Policy and Informatics, Institute of Science Tokyo Graduate School of Medical and Dental Sciences, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munetoshi","family":"Sugiura","sequence":"additional","affiliation":[{"name":"Department of Drug Safety and Risk Management, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250527","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1001\/jamaneurol.2019.0006","article-title":"Worldwide incidence of aneurysmal subarachnoid hemorrhage according to region, time period, blood pressure, and smoking prevalence in the population: a systematic review and meta-analysis.","volume":"76","author":"Etminan","year":"2019","journal-title":"JAMA Neurol"},{"key":"R2-20250527","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1111\/cns.13222","article-title":"Clinical and experimental aspects of aneurysmal subarachnoid hemorrhage.","volume":"25","author":"Daou","year":"2019","journal-title":"CNS Neurosci Ther"},{"key":"R3-20250527","first-page":"e314","article-title":"2023 Guideline for the management of patients with aneurysmal subarachnoid hemorrhage: a guideline from the American Heart Association\/American Stroke Association.","volume":"54","author":"Hoh","year":"2023","journal-title":"Stroke"},{"key":"R4-20250527","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1001\/jamaneurol.2021.4346","article-title":"Twenty-year change in severity and outcome of ischemic and hemorrhagic strokes.","volume":"79","author":"Toyoda","year":"2022","journal-title":"JAMA Neurol"},{"key":"R5-20250527","doi-asserted-by":"crossref","first-page":"571","DOI":"10.3171\/jns.1992.76.4.0571","article-title":"Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Results of a prospective placebo\u2010controlled double-blind trial.","volume":"76","author":"Shibuya","year":"1992","journal-title":"J Neurosurg"},{"key":"R6-20250527","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/0090-3019(91)90228-2","article-title":"Efficacy and toxicity of thromboxane synthetase inhibitor for cerebral vasospasm after subarachnoid hemorrhage.","volume":"36","author":"Tokiyoshi","year":"1991","journal-title":"Surg Neurol"},{"key":"R7-20250527","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1177\/17474930221090347","article-title":"Japan Stroke Society guideline 2021 for the treatment of stroke.","volume":"17","author":"Miyamoto","year":"2022","journal-title":"Int J Stroke"},{"key":"R8-20250527","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1186\/s12883-021-02303-8","article-title":"Effectiveness comparisons of drug therapies for postoperative aneurysmal subarachnoid hemorrhage patients: network meta-analysis and systematic review.","volume":"21","author":"Yu","year":"2021","journal-title":"BMC Neurol"},{"key":"R9-20250527","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s12975-018-0650-y","article-title":"Dose-dependent inhibitory effects of cilostazol on delayed cerebral infarction after aneurysmal subarachnoid hemorrhage.","volume":"10","author":"Suzuki","year":"2019","journal-title":"Transl Stroke Res"},{"key":"R10-20250527","doi-asserted-by":"crossref","first-page":"1296995","DOI":"10.3389\/fneur.2023.1296995","article-title":"Japanese nationwide questionnaire survey on delayed cerebral infarction due to vasospasm after subarachnoid hemorrhage.","volume":"14","author":"Nishikawa","year":"2023","journal-title":"Front Neurol"},{"key":"R11-20250527","first-page":"19","article-title":"Clinical epidemiology and health services research using the diagnosis procedure combination database in Japan.","volume":"7","author":"Yasunaga","year":"2015","journal-title":"Asia Pac J Dis Manag"},{"key":"R12-20250527","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2188\/jea.JE20200288","article-title":"History and profile of Diagnosis Procedure Combination (DPC): development of a real data collection system for acute inpatient care in Japan.","volume":"31","author":"Hayashida","year":"2021","journal-title":"J Epidemiol"},{"key":"R13-20250527","doi-asserted-by":"crossref","first-page":"e002736","DOI":"10.1136\/bmjopen-2013-002736","article-title":"The eye response test alone is sufficient to predict stroke outcome \u2013 reintroduction of Japan Coma Scale: a cohort study.","volume":"3","author":"Shigematsu","year":"2013","journal-title":"BMJ Open"},{"key":"R14-20250527","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2147\/CLEP.S288518","article-title":"Validation of ICD-10-CM diagnosis codes for identification of patients with acute hemorrhagic stroke in a national health insurance claims database.","volume":"13","author":"Hsieh","year":"2021","journal-title":"Clin Epidemiol"},{"key":"R15-20250527","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1177\/1545968306294729","article-title":"Establishing the minimal clinically important difference of the Barthel Index in stroke patients.","volume":"21","author":"Hsieh","year":"2007","journal-title":"Neurorehabil Neural Repair"},{"key":"R16-20250527","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2176\/nmc.ra.2017-0057","article-title":"Aneurysmal subarachnoid hemorrhage in the elderly over age 75: a systematic review.","volume":"57","author":"Ohkuma","year":"2017","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"R17-20250527","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2188\/jea.JE20220147","article-title":"Development and validation of a novel method for converting the Japan Coma Scale to Glasgow Coma Scale.","volume":"33","author":"Nakajima","year":"2023","journal-title":"J Epidemiol"},{"key":"R18-20250527","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12883-017-0815-4","article-title":"Development and validation of a score for evaluating comprehensive stroke care capabilities: J-ASPECT Study.","volume":"17","author":"Kada","year":"2017","journal-title":"BMC Neurol"},{"key":"R19-20250527","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data.","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"key":"R20-20250527","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2176\/nmc.46.421","article-title":"Effect of fasudil hydrochloride, a protein kinase inhibitor, on cerebral vasospasm and delayed cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage -results of a randomized trial of fasudil hydrochloride versus nimodipine.","volume":"46","author":"Zhao","year":"2006","journal-title":"Neurol Med Chir"},{"key":"R21-20250527","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/jcbfm.2011.169","article-title":"Delayed cerebral ischemia and spreading depolarization in absence of angiographic vasospasm after subarachnoid hemorrhage.","volume":"32","author":"Woitzik","year":"2012","journal-title":"J Cereb Blood Flow Metab"},{"key":"R22-20250527","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/ana.25361","article-title":"Cilostazol decreases duration of spreading depolarization and spreading ischemia after aneurysmal subarachnoid hemorrhage.","volume":"84","author":"Sugimoto","year":"2018","journal-title":"Ann Neurol"},{"key":"R23-20250527","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s12028-021-01330-0","article-title":"Association between spreading depolarization and delayed cerebral ischemia after subarachnoid hemorrhage: post hoc analysis of a randomized trial of the effect of cilostazol on delayed cerebral ischemia.","volume":"35","author":"Kawano","year":"2021","journal-title":"Neurocrit Care"},{"key":"R24-20250527","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jocn.2016.05.006","article-title":"Elderly age associated with poor functional outcome after rupture of anterior communicating artery aneurysms.","volume":"34","author":"Rinaldo","year":"2016","journal-title":"J Clin Neurosci"},{"key":"R25-20250527","doi-asserted-by":"crossref","first-page":"e0230953","DOI":"10.1371\/journal.pone.0230953","article-title":"Effect of treatment modality and cerebral vasospasm agent on patient outcomes after aneurysmal subarachnoid hemorrhage in the elderly aged 75 years and older.","volume":"15","author":"Ido","year":"2020","journal-title":"PLoS One"},{"key":"R26-20250527","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.3171\/2016.12.JNS161039","article-title":"Effects of treatment modality on in-hospital outcome in patients with subarachnoid hemorrhage: a nationwide study in Japan (J-ASPECT Study).","volume":"128","author":"Kurogi","year":"2018","journal-title":"J Neurosurg"},{"key":"R27-20250527","doi-asserted-by":"crossref","first-page":"929","DOI":"10.3171\/2019.12.JNS192584","article-title":"Effects of case volume and comprehensive stroke center capabilities on patient outcomes of clipping and coiling for subarachnoid hemorrhage.","volume":"134","author":"Kurogi","year":"2021","journal-title":"J Neurosurg"},{"key":"R28-20250527","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3171\/2016.5.JNS152900","article-title":"Effect of statin treatment on vasospasm-related morbidity and functional outcome in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis.","volume":"127","author":"Shen","year":"2017","journal-title":"J Neurosurg"},{"key":"R29-20250527","doi-asserted-by":"crossref","first-page":"387","DOI":"10.4236\/jbbs.2020.1010024","article-title":"Effectiveness and influencing factors of comprehensive rehabilitation therapy in patients with aneurysmal subarachnoid hemorrhage.","volume":"10","author":"Wu","year":"2020","journal-title":"J Behav Brain Sci"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000042544","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T04:00:57Z","timestamp":1748318457000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000042544"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,23]]},"references-count":29,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000042544","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,23]]}}}